Brief Motivational Enhancement Therapy for Concurrent Disorders

NCT01924039 | Terminated

• 1 other identifier: 055/2013
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators are proposing a project that will examine the effectiveness of brief motivational enhancement therapy in a population with concurrent psychotic disorders and substance use disorders. This study will represent an emerging line of inquiry, as best practice interventions with this concurrent disordered (CD) populations are yet to be established.

Conditions

Psychosis; Substance Use

Keywords

Psychosis; Substance Use; Motivational Enhancement Therapy

Outcome Measures

Primary Outcomes (1)

• CD group attendance

  The primary outcome engagement with outpatient CD service as measured by CD group attendance.

  2 weeks

Secondary Outcomes (1)

• Alcohol Use Scale (AUS)/Drug Use Scale (DUS)

  2 weeks and 3 months

Other Outcomes (1)

• Working Alliance Inventory

  2 weeks

Study Arms (2)

Brief Motivational Enhancement Therapy

EXPERIMENTAL

Behavioral: Brief Motivational Enhancement Therapy

treatment as usual

OTHER

Behavioral: Brief Motivational Enhancement Therapy; Other: treatment as usual

Interventions

Brief Motivational Enhancement Therapy BEHAVIORAL

The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.

Brief Motivational Enhancement Therapy; treatment as usual

treatment as usual OTHER

Treatment as usual includes case management as well as psychiatric appointments.

treatment as usual

Eligibility Criteria

• Age: 16 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Between the ages of 16-65
• DSM-IV Diagnoses of a psychotic disorder and a substance use disorder (tobacco, alcohol and/or drug)
• Fluent English speaker
• Capable of giving written informed consent

You may not qualify if:

• Any medical or neuropsychiatric condition, illness or disorder (e.g. unstable angina, severe dementia) that could compromise attendance to outpatient appointments.
• Inability to provide informed consent.

Sponsors & Collaborators

• Centre for Addiction and Mental Health: lead

Study Sites (1)

Centre for Addiction and Mental Health

Toronto, Ontario, M5T 1R8, Canada

Location

MeSH Terms

Conditions

Psychotic Disorders; Substance-Related Disorders

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Chemically-Induced Disorders

Study Officials

• Yarissa Herman, D.Psych

  Centre for Addiction and Mental Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Psychologist

Study Record Dates

• First Submitted: August 7, 2013
• First Posted: August 16, 2013
• Study Start: June 1, 2013
• Primary Completion: September 1, 2014
• Study Completion: December 1, 2014
• Last Updated: December 17, 2014

Record last verified: 2014-12

Locations

CA (1)